Target intelligence / Profile preview

Primary microRNA-17~92 cluster transcript (pri-miR-17~92) (pri-miR-17~92)

Target
pri-miR-17~92
Molecular classification
Non-coding RNA, Primary microRNA transcript, Polycistronic microRNA cluster
01

Overview

The primary microRNA-17~92 cluster transcript (pri-miR-17~92) is a polycistronic non-coding RNA encoded by the MIR17HG gene on chromosome 13 (He et al., 2005, Nature 435:828-833). It serves as the precursor for six mature microRNAs: miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, and miR-92a-1, which are critical regulators of gene expression (Mogilyansky & Rigoutsos, 2013, Cell Death Differ. 20(12):1603-14). This cluster, often termed "Oncomir-1," is frequently amplified or overexpressed in a wide range of cancers, including B-cell lymphomas and lung cancer, where it drives oncogenesis by promoting cell cycle progression and inhibiting apoptosis (Concepcion et al., 2012, FEBS J. 279(2):202-10). In normal physiology, the transcript is essential for proper development of the heart, lungs, and immune system (Velu & Grimes, 2012, Genes Cancer 3(11-12):602-9). Therapeutic strategies targeting pri-miR-17~92 include antisense oligonucleotides and small molecules that bind to specific secondary structures within the transcript to block its processing by the Drosha-DGCR8 complex (Disney et al., 2016, ACS Chem. Biol. 11(6):1720-8). While targeting this cluster holds significant potential for treating overexpressing tumors, challenges include achieving tissue specificity and avoiding the disruption of its essential roles in normal cellular homeostasis.

Other names
MIR17HGOncomir-1C13orf25miR-17-92 clusterPrimary microRNA-17-92
02

Mechanism of action

Inhibition of Drosha-mediated processing, antisense-mediated sequestration, and RNA interference-mediated degradation of the primary transcript.

03

Biological functions

Cell proliferationApoptosis inhibitionAngiogenesisCell cycle regulationB-cell development
04

Disease associations

B-cell lymphomaLung cancerBreast cancerFeingold syndromeCardiovascular disease
05

Safety considerations

Developmental toxicityCardiac dysfunctionImmune system suppressionOff-target RNA binding
06

Interacting drugs

Antagomir-17

2 more in the full profile.

07

Biomarkers

miR-17-92 cluster expression levelsMIR17HG gene amplificationCirculating miR-19a levels

Beyond the preview

Go deeper on Primary microRNA-17~92 cluster transcript (pri-miR-17~92) (pri-miR-17~92).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Primary microRNA-17~92 cluster transcript (pri-miR-17~92) (pri-miR-17~92).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call